Press, O W <br/><br/>
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.  [electronic resource] 

 -  Lancet (London, England)  Aug 1995 
 - 336-40 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0140-6736 
<br/><br/><label>Standard No.: </label>10.1016/s0140-6736(95)92225-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--immunology<br/>Antigens, CD--immunology<br/>B-Lymphocytes--immunology<br/>Cohort Studies<br/>Combined Modality Therapy<br/>Disease-Free Survival<br/>Female<br/>Follow-Up Studies<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Iodine Radioisotopes--administration & dosage<br/>Lymphoma, B-Cell--mortality<br/>Male<br/>Middle Aged<br/>Radioimmunotherapy--adverse effects<br/>Remission Induction<br/>Survival Rate